肝细胞来源生物标志物预测Child-Pugh A级酒精性肝硬化患者2年肝脏相关事件
在500例Child-Pugh A级酒精性肝硬化患者中,评估血浆角蛋白-18和肝细胞来源大细胞外囊泡预测2年肝脏相关事件的能力。入组时无活跃饮酒者(n=419)中角蛋白-18独立预测事件,角蛋白-18>285 U/L且FibroTest>0.74者2年累积发生率为24%,其他组为5%至14%。入组时有活跃饮酒者(n=81)中肝细胞大细胞外囊泡独立预测事件,其>50 U/L且FibroTest>0.74者2年累积发生率为62%,其他组为8%至13%。
要点
- 角蛋白-18和肝细胞大细胞外囊泡浓度随饮酒量增加而升高。
- 无活跃饮酒者中,角蛋白-18>285 U/L联合FibroTest>0.74者2年累积发生率为24%。
- 有活跃饮酒者中,肝细胞大细胞外囊泡>50 U/L联合FibroTest>0.74者2年累积发生率为62%。
核心结论
- 在Child-Pugh A级酒精性肝硬化患者中,将肝细胞来源生物标志物与FibroTest或MELD评分联合可识别2年肝脏相关事件高危患者,并可用于临床试验中的风险分层和患者选择。
研究设计与样本
- 在500例Child-Pugh A级酒精性肝硬化患者中测量血浆角蛋白-18和肝细胞大细胞外囊泡浓度,分析其单独或联合MELD和FibroTest评分预测2年肝脏相关事件的能力,并考虑入组时和随访期间的饮酒情况。
主要发现
- 角蛋白-18和肝细胞大细胞外囊泡浓度随饮酒量增加而升高。
- 入组时无活跃饮酒者(n=419)中,角蛋白-18浓度独立于FibroTest和MELD预测2年肝脏相关事件。
- 角蛋白-18>285 U/L且FibroTest>0.74者2年肝脏相关事件累积发生率为24%,其他患者组为5%至14%。
- 角蛋白-18>285 U/L联合MELD>10获得相似结果。
- 入组时有活跃饮酒者(n=81)中,肝细胞大细胞外囊泡独立于FibroTest和MELD预测2年肝脏相关事件。
关键数值与推荐
- 无活跃饮酒者中,角蛋白-18>285 U/L且FibroTest>0.74者2年肝脏相关事件累积发生率为24%,其他组为5%至14%。
- 有活跃饮酒者中,肝细胞大细胞外囊泡>50 U/L且FibroTest>0.74者2年肝脏相关事件累积发生率为62%,其他组为8%至13%。
临床怎么用
- 作者认为,识别出的肝脏相关事件高危患者是强化监测(如转诊至三级医疗中心、强化危险因素控制)和纳入临床试验的目标人群。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: In patients with compensated alcohol-related cirrhosis, reliable prognostic biomarkers are lacking. Keratin-18 and hepatocyte-derived large extracellular vesicle (lEV) concentrations reflect disease activity, but their ability to predict liver-related events is unknown. METHODS: We measured plasma keratin-18 and hepatocyte lEV concentrations in 500 patients with Child-Pugh class A alcohol-related cirrhosis. The ability of these hepatocyte-derived biomarkers, alone or combined with model for end-stage liver disease (MELD) and FibroTest scores, to predict liver-related events at 2 years was analyzed, taking into account the alcohol consumption at inclusion and during follow-up. RESULTS: Keratin-18 and hepatocyte lEV concentrations increased with alcohol consumption. In patients without active alcohol consumption at enrollment (n = 419), keratin-18 concentration predicted liver-related events at 2 years, independently of FibroTest and MELD. Patients with both keratin-18 concentrations >285 U/L and FibroTest >0.74 had a 24% cumulative incidence of liver-related events at 2 years, vs. 5% to 14% in other groups of patients. Similar results were obtained when combining keratin-18 concentrations >285 U/L with MELD >10. In patients with active alcohol consumption at enrollment (n = 81), hepatocyte lEVs predicted liver-related events at 2 years, independently of FibroTest and MELD. Patients with both hepatocyte lEV concentrations >50 U/L and FibroTest >0.74 had a 62% cumulative incidence of liver-related events at 2 years, vs. 8% to 13% in other groups of patients. Combining hepatocyte lEV concentrations >50 U/L with MELD >10 had a lower discriminative ability. Similar results were obtained when using decompensation of cirrhosis, defined according to Baveno VII criteria, as an endpoint. CONCLUSION: In patients with Child-Pugh class A alcohol-related cirrhosis, combining hepatocyte-derived biomarkers with FibroTest or MELD scores identifies patients at high risk of liver-related events, and could be used for risk stratification and patient selection in clinical trials. IMPACT AND IMPLICATIONS: In patients with compensated alcohol-related cirrhosis, reliable predictors of outcome are lacking. In patients with Child-Pugh class A alcohol-related cirrhosis, combining hepatocyte-derived biomarkers (keratin-18 and hepatocyte-large extracellular vesicles) with FibroTest or MELD scores identifies those at high risk of liver-related events at 2 years. The identified patients at high risk of liver-related events are the target-of-choice population for intensive surveillance (e.g., referral to tertiary care centers; intensive control of risk factors) and inclusion in clinical trials.
引用
- Elkrief L, Ganne-Carrié N, Manceau H, et al. Hepatocyte-derived biomarkers predict liver-related events at 2 years in Child-Pugh class A alcohol-related cirrhosis. J Hepatol. 2023. PMID: 37302582. doi:10.1016/j.jhep.2023.05.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。